EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Funded Projects
Based on current funded research
Updated November 1, 2023
Data provided by University at Buffalo Sponsored Projects Services
| Award Principal Investigator | Award Name | Award Type | Sponsor Name | Award Start Date | Award End Date | Total Cost |
|---|---|---|---|---|---|---|
| Balthasar, Dr. Joseph | Center for Protein Therapeutics | Nonfederal | Multiple Sponsors | 01-Sep-17 | 31-Aug-24 | 11,024,501.70 |
| Balthasar, Dr. Joseph | Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors | Federal | National Cancer Institute | 01-Jun-20 | 31-May-25 | 1,799,963.00 |
| Balthasar, Dr. Joseph | Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization | Federal | National Cancer Institute | 01-Jun-21 | 31-May-26 | 1,809,602.00 |
| Balthasar, Dr. Joseph | Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia | Federal | National Cancer Institute | 01-Jan-23 | 31-Jan-28 | 2,137,191.00 |
| Balthasar, Dr. Joseph | Improving antibody distribution with transient antigen binding inhibition | Nonfederal | Empire Discover Institute | 08-Dec-22 | 07-Dec-23 | 180,000.00 |
| Balu-Iyer, Dr. Sathy V. | Lipid mediated oral tolerance | Federal | National Institute of Allergy & Infectious Disease | 16-Jun-22 | 31-May-27 | 2,327,530.00 |
| Balu-Iyer, Dr. Sathy V. | Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A | Federal | National Heart Lung and Blood Institute | 27-Mar-23 | 28-Feb-25 | 1,132,306.00 |
| Balu-Iyer, Dr. Sathy V. | Oral administration of Tolerance-Inducing Lyso-Phosphatidyl Serine (TIPS) nanoparticles formulated with insulin to treat T1D in NOD mice | Nonfederal | Empire Discovery Institute | 12-Jun-23 | 11-Jun-24 | 98,793.00 |
| Bednarczyk, Dr. Edward M. | C19: Chronic Disease Medication Utilization and the Novel Coronavirus Disease 2019 (COVID-19) Infection | Nonfederal | American College of Clinical Pharmacy | 01-Jan-21 | 31-Dec-24 | 600.00 |
| Bednarczyk, Dr. Edward M. | NYS Prescription Monitoring CE Program | Federal Flow Through | Island Peer Review Organization | 01-Sep-21 | 31-Dec-23 | 188,394.00 |
| Bies, Dr. Robert R. | Physiologically-based model of the female reproductive tract: vaginal and intrauterine delivery components- Support New Approaches to Improve Product Manufacturing and Quality | Federal | US Food and Drug Administration | 26-Sep-18 | 25-Jan-24 | 940,749.00 |
| Bies, Dr. Robert R. | Pharmacokinetics of sedatives - Understanding a modifiable risk factor for pediatric delirium | Federal Flow Through | Childrens Research Institute | 01-Sep-19 | 31-Jul-24 | 121,811.00 |
| Bies, Dr. Robert R. | Long Acting Film Technology for Contraception and HIV Prevention (LATCH) | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Feb-21 | 31-Jan-24 | 219,856.00 |
| Bies, Dr. Robert R. | Evaluation of safety and pharmacokinetics of naltrexone implant | Federal Flow Through | Research Foundation for Mental Hygiene | 01-Mar-21 | 29-Feb-24 | 217,842.00 |
| Bies, Dr. Robert R. | The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC) | Federal Flow Through | Trustees of Indiana University | 10-Sep-2021 | 31-Jul-26 | 1,895,627.00 |
| Bies, Dr. Robert R. | Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence, MATRIX | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Dec-2021 | 31-Dec-26 | 1,201,995.00 |
| Bies, Dr. Robert R | Reproductive Tract PBPK & Exposure Modeling | Nonfederal | Magee-Womens Research Institute and Foundation | 07-Nov-22 | 30-Sep-24 | 189,280.00 |
| Bies, Dr. Robert R | Application of PBPK model of the Female Reproductive Tract (FRT) | Nonfederal | Bill and Melinda Gates Foundation | 03-Oct-23 | 31-Aug-24 | 66,319.00 |
| Clark, Dr. Collin M. | A Pilot Pharmacist-to-Pharmacist Hand-off Intervention During Transitions of Care | Nonfederal | American Association of Colleges of Pharmacy | 01-Mar-23 | 28-Feb-24 | 7,500.00 |
| Daly, Dr. Christopher | Effectiveness of a Social Determinants of Health Pharmacy Program Implemented in Community Pharmacies | Federal Flow Through | Island Peer Review Organization | 01-Aug-22 | 07-Nov-24 | 68,254.00 |
| Daly, Dr. Christopher | Scaling Payer and Community Pharmacy Partnerships for Patient Care | Nonfederal | Community Pharmacy Foundation | 01-Feb-23 | 31-May-24 | 42,500.00 |
| Fusco, Dr. Nicholas | Preparing Health Professions Students to Address Medical Misinformation and Vaccine Hesitancy Through Competency-Based Interprofessional Instructional Design Strategies | Nonfederal | American Association of Colleges of Pharmacy | 01-July-23 | 30-Jun-24 | 4,000.00 |
| Gallo, Dr. James | Targeting trained immunity in transplantation - Core B | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 01-Jun-23 | 31-Mar-28 | 219,345.00 |
| Jacobs, Dr. David Matthew | Integrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPD | Federal | National Heart Lung and Blood Institute | 01-Apr-21 | 31-Mar-26 | 962,055.00 |
| Jacobs, Dr. David Matthew | Development of an Economic Model and Return on Investment Tool to Support Sustainable Community Pharmacy Social Determinant of Health Programs | Nonfederal | Community Pharmacy Foundation | 01-Jun-23 | 31-May-24 | 43,010.00 |
| Jusko, Dr. William J. | Mechanistic Pharmacokinetics and Pharmacodynamics | Federal | National Institute of General Medical Sciences | 01-May-19 | 30-Apr-24 | 2,891,677.00 |
| Jusko, Dr. William J. | Training Program in Pharmacokinetics and Pharmacodynamics | Nonfederal | GlaxoSmithKline | 03-Feb-21 | 30-Aug-25 | 512,400.00 |
| Lao, Dr. Yeh-Hsing Sima | Nanoformulated CRISPR Ribonucleoproteins for Ultrasound-Facilitated Brain Gene Editing | Federal | National Inst of Neurological Disorders & Stroke | 01-Jul-23 | 30-Jun-25 | 442,000.00 |
| Ma, Dr. Qing | Doravirine Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals | Nonfederal | Merck Sharp and Dohme Limited Liability Corporation | 04-Jun-19 | 30-Jun-24 | 167,705.69 |
| Ma, Dr. Qing | Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV | Federal | National Institute on Aging | 01-May-20 | 28-Feb-25 | 4,006,139.00 |
| Ma, Dr. Qing | Bictegravir in the Elderly Living with HIV: Impact of Polypharmacy and Multimorbidity | Nonfederal | Gilead Sciences Incorporated | 01-Oct-19 | 30-Sep-24 | 155,175.00 |
| Mager, Dr. Donald E. | Optimizing GVHD Prevention with Systems Pharmacology Models | Federal Flow Through | Beckman Research Institute of the City of Hope | 01-Jun-19 | 31-May-24 | 646,324.00 |
| Mager, Dr. Donald E. | Novel combination therapy for colorectal and esophagogastric cancers | Nonfederal | Health Research Inc. | 01-Jun-22 | 30-Jun-24 | 12,075.00 |
| Morse, Dr. Gene | ACTG Precautionary and Prohibited Medications Database | Federal Flow Through | Regents of the University of California Los Angeles | 01-Dec-20 | 30-Nov-23 | 570,000.00 |
| Morse, Dr. Gene | University of Rochester HIV/AIDS Clinical Trial Unit - AWD00003932 | Federal Flow Through | University of Rochester | 01-Dec-2020 | 30-Nov-27 | 126,559.00 |
| Morse, Dr. Gene | HIV Clinical Pharmacology & Therapeutics Research Training Program | Federal | Fogarty International Center | 01-Mar-22 | 31-Jan-27 | 1,507,744.94 |
| Morse, Dr. Gene | Clinical Pharmacology Quality Assurance (CPQA) | Federal | National Institute of Allergy & Infectious Disease | 30-May-22 | 29-May-29 | 14,339,193.00 |
| Morse, Dr. Gene | LC-MS/MS Assay Development and Validation for CBD and CBD hydroxy metabolite | Nonfederal | Ananda Scientific | 26-Apr-22 | 25-Feb-24 | 62,441.00 |
| Morse, Dr. Gene | CENTER FOR INTEGRATED GLOBAL BIOMEDICAL SCIENCES | Nonfederal | Abbott Laboratories | 23-Nov-22 | 31-Aug-24 | 174,900.00 |
| Morse, Dr. Gene | Global Infectious Diseases Research Training Program | Federal | Fogarty International Center | 01-Mar-23 | 31-Dec-27 | 1,833,196.00 |
| Prescott, Dr. Gina | Hypertension Cascade of Care in Marginalized Populations | Nonfederal | NYS Chapter of American College of Clinical Pharmacy | 01-Jun-23 | 30-Nov-23 | 3,000.00 |
| Qu, Dr. Jun | Highly sensitive multiplexed targeted mass spectrometric assays of proteins/peptides of significance in obesity research | Federal Flow Through | Pacific Northwest National Laboratory | 19-Feb-20 | 31-Jul-24 | 618,520.00 |
| Qu, Dr. Jun | Extracellular Vesicle treatment and age-related neuropathology in non-human primates | Federal Flow Through | Trustees of Boston University | 15-Sep-20 | 30-Apr-25 | 189,717.00 |
| Qu, Dr. Jun | Role of Type 2 Immune Response in Pancreatic Cancer Tumorgenisis | Federal Flow Through | Health Research Inc. | 15-Jul-21 | 31-Dec-23 | 24,659.00 |
| Qu, Dr. Jun | Neuroinflammation-related phosphoprotein signaling pathways as potential therapeutic targets for GWI using an established animal model | Federal Flow Through | Virginia Commonwealth University | 01-Feb-23 | 31-Jan-24 | 39,103.00 |
| Qu, Dr. Jun | Mitochondrial Defects in the Retinal Pigment Epithelium and the CFH Risk Allele for Age-related Macular Degeneration | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 30-Jun-26 | 257,000.00 |
| Qu, Dr. Jun | Deciphering the Mechanisms Associated with High-risk AMD genotypes for ARMS2/HTRA1 and Complement Factor H | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 31-Aug-25 | 191,400.00 |
| Qu, Dr. Jun | Mechanisms underlying extracellular vesicle mediated changes in inflammation, neural circuitry and plasticity following cortical injury in aged monkeys | Federal Flow Through | Trustees of Boston University | 15-Jul-22 | 30-Jun-27 | 350,859.00 |
| Ramanathan, Dr. Murali | The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression | Federal | US Army Medical Research Acquisition Activity | 1-Jul-20 | 30-Jun-24 | 957,000.00 |
| Shah, Dr. Dhavalkumar | Development of organ-specific quantitative systems toxicology models for antibody-drug conjugates | Nonfederal | AstraZeneca Pharmaceuticals LP | 1-Apr-22 | 09-Oct-25 | 465,771.00 |
| Sprowl, Dr. Jason Arthur | Regulation of hepatic uptake transporters by tyrosine kinases | Federal | National Institute of General Medical Sciences | 15-Sep-2021 | 31-Aug-26 | 2,321,588.00 |
| Sprowl, Dr. Jason Arthur | Role of MCT6 in mediating cisplatin-induced ototoxicity | Federal | National Inst on Deafness & Other Comm Disorders | 01-Apr-23 | 31-Mar-25 | 432,182.00 |
| Tornatore, Dr. Kathleen M. | Age and Race Influences on Immunosuppression after Renal Transplant | Federal | National Institute on Aging | 15-Aug-18 | 30-Jun-24 | 3,507,814.00 |
| Tsuji, Dr. Brian T. | Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | Federal | National Institute of Allergy & Infectious Disease | 20-Dec-19 | 30-Nov-24 | 3,920,362.00 |
| Tsuji, Dr. Brian T. | Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa | Federal | National Institute of Allergy & Infectious Disease | 24-May-22 | 30-Apr-27 | 3,850,992.00 |
| Woo, Dr. Sukyung | Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition | Federal | National Cancer Institute | 01-Dec-2021 | 30-Nov-26 | 2,010,125.00 |
| Woo, Dr. Sukyung | Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold | Federal Flow Through | Board of Regents of the University of Oklahoma | 01-Jul-22 | 30-Jun-27 | 431,303.00 |
| You, Dr. Young Jae | Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers | Federal | National Cancer Institute | 13-Jul-22 | 30-Jun-27 | 2,098,942.00 |
| You, Dr. Young Jae | Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation | Federal | National Institute of General Medical Sciences | 01-Aug-23 | 31-Jul-27 | 1,372,031.00 |